| Literature DB >> 35659087 |
Yongzhang Zhu1,2, Li Shi3, Yige Zeng4, Dongri Piao5, Yingbo Xie6, Juan Du6, Meng Gao6, Wei Gao6, Junli Tian6, Jun Yue6, Min Li1,2, XiaoKui Guo7,8, Yufeng Yao9, YaoXia Kang10,11.
Abstract
BACKGROUND: Brucellosis poses a serious threat to human and animal health, particularly in developing countries such as China. The Inner Mongolia Autonomous Region is one of the most severely brucellosis-endemic provinces in China. Currently, the host immune responses functioning to control Brucella infection and development remain poorly understood. The aim of this study is to further clarify the key immunity characteristics of diverse stages of brucellosis in Inner Mongolia.Entities:
Keywords: CD4+ T cells; CD8+ T cells; Human brucellosis; TLR2; TLR4; Th cells
Mesh:
Substances:
Year: 2022 PMID: 35659087 PMCID: PMC9167523 DOI: 10.1186/s40249-022-00989-7
Source DB: PubMed Journal: Infect Dis Poverty ISSN: 2049-9957 Impact factor: 10.485
Description of the demographic characteristics and diagnosis of brucellosis patients
| Acute ( | Chronic ( | Healthy ( | Inapparent ( | Recovery ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subgrouping criteria | ||||||||||||
| Epidemiologic exposure history | ||||||||||||
| Symptoms and signs | − | |||||||||||
| Rose Bengal Plate agglutination Test | ||||||||||||
| Standard agglutination test | ||||||||||||
| Holding time (Months) | ≤ 6 | > 6 | − | Unknown | Unknown | |||||||
| Medication history | ||||||||||||
| Demographic features | ||||||||||||
| Gender (Male/Female) | 95/42 | 240/76 | 105/41 | 26/9 | 77/22 | 0.519 | ||||||
| Age (Years) | 50.65 ± 11.36 | 53.28 ± 9.33 | 49.38 ± 12.90 | 46.71 ± 10.37 | 51.01 ± 10.01 | < 0.001 | ||||||
| Hematology | ||||||||||||
| Red blood cells (× 1012/L) | 4.98 ± 0.59 | 4.96 ± 0.57 | 4.92 ± 0.75 | 5.04 ± 0.51 | 5.04 ± 0.49 | 0.567 | ||||||
| Hemoglobin (g/L) | 146.41 ± 20.60 | 149.54 ± 16.23 | 146.58 ± 22.32 | 150.69 ± 16.39 | 150.98 ± 15.25 | 0.157 | ||||||
| White blood cells (× 109/L) | 5.48 ± 1.46 | 5.64 ± 1.52 | 5.82 ± 1.59 | 5.94 ± 1.46 | 5.93 ± 1.69 | 0.127 | ||||||
| Lymphocyte (× 109/L) | 1.94 ± 0.61 | 1.87 ± 0.58 | 1.88 ± 0.60 | 1.85 ± 0.43 | 1.97 ± 0.66 | 0.493 | ||||||
| Neutrophil (× 109/L) | 2.95 ± 1.38 | 3.27 ± 1.33 | 3.45 ± 1.42 | 3.67 ± 1.30 | 3.57 ± 1.30 | 0.001 | ||||||
| Platelets (× 109/L) | 171.92 ± 67.54 | 169.96 ± 65.17 | 172.79 ± 61.00 | 170.97 ± 55.86 | 157.38 ± 49.38 | 0.361 | ||||||
| Neutrophil/lymphocyte ratio | 1.62 ± 0.91 | 1.85 ± 0.89 | 1.98 ± 1.06 | 2.08 ± 0.97 | 1.98 ± 1.11 | 0.009 | ||||||
| Platelets/lymphocyte ratio | 81.64 ± 25.68 | 86.84 ± 24.60 | 84.42 ± 24.60 | 84.85 ± 18.09 | 86.37 ± 36.90 | 0.449 | ||||||
| Serum biochemistry | ||||||||||||
| Alanine transaminase (U/L) | 31.28 ± 27.83 | 28.02 ± 19.05 | 26.93 ± 16.24 | 26.74 ± 21.72 | 32.90 ± 20.88 | 0.107 | ||||||
+ means have or the test is positive, − means have not or the test is negative
Progressive significance of ROC curves for hematological parameters and proportions
| Acute-Chronic | Acute-Healthy | Acute-Inapparent | Acute-Recovery | Chronic-Healthy | Chronic-Inapparent | Chronic-Recovery | Healthy-Inapparent | Healthy-Recovery | Inapparent-Recovery | |
|---|---|---|---|---|---|---|---|---|---|---|
| Hematology | ||||||||||
| Red blood cells (× 1012/L) | 0.905 | 1.000 | 0.513 | 0.541 | 0.915 | 0.483 | 0.449 | 0.527 | 0.516 | 0.763 |
| Hemoglobin (g/L) | 0.097 | 0.552 | 0.402 | 0.153 | 0.319 | 0.992 | 0.724 | 0.636 | 0.306 | 0.878 |
| White blood cells (× 109/L) | 0.457 | 0.081 | 0.124 | 0.169 | 0.199 | 0.345 | 0.399 | 0.800 | 0.947 | 0.816 |
| Lymphocyte (× 109/L) | 0.169 | 0.407 | 0.276 | 0.962 | 0.613 | 0.924 | 0.168 | 0.751 | 0.450 | 0.366 |
| Neutrophil (× 109/L) | 0.027 | 0.006 | 0.024 | 0.006 | 0.291 | 0.324 | 0.195 | 0.639 | 0.785 | 0.848 |
| Platelets (× 109/L) | 0.821 | 0.576 | 0.927 | 0.068 | 0.412 | 0.762 | 0.077 | 0.828 | 0.010 | 0.097 |
| NLR | 0.006 | 0.021 | 0.030 | 0.044 | 0.956 | 0.448 | 0.932 | 0.458 | 0.818 | 0.490 |
| PLR | 0.025 | 0.216 | 0.133 | 0.509 | 0.380 | 0.823 | 0.197 | 0.505 | 0.681 | 0.329 |
| Serum biochemistry | ||||||||||
| Alanine transaminase (U/L) | 0.317 | 0.506 | 0.221 | 0.254 | 0.834 | 0.275 | 0.017 | 0.329 | 0.062 | 0.027 |
NLR neutrophil/lymphocyte ratio, PLR platelets/lymphocyte ratio
Fig. 1The proportions of CD3+CD4+ T cells (a) and CD3+CD8+ T cells (b) and the CD4+/CD8+ ratio (c) in the peripheral blood from different groups. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
Fig. 2The proportions of Th1 (a), Th2 (b), and Th-17a (c) in the peripheral blood from different groups. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
Fig. 3Comparison of the levels of TLR2 and TLR4 and the co-expression of TLR2,4 in lymphocytes (a‒c), monocytes (d‒f), and granulocyte (g‒i) among the five groups of participants. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
Fig. 4Heatmaps with Pearson correlation coefficient. The expression of TLR2 and TLR4 in the lymphocytes, monocytes and granulocytes among the acute (a), chronic (b), healthy (c), inapparent (d), and recovery (e) groups. The color density represents the magnitude of the correlations, with blue color indicating positive and red color indicating negative. L lymphocytes, M monocytes, G granulocytes